+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Auranofin Market - Global Forecast 2026-2032- Product Image
Auranofin Market - Global Forecast 2026-2032- Product Image
New

Auranofin Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 190 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6082722
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

As therapeutic repurposing gains momentum and commercial frameworks evolve, the auranofin market is experiencing renewed strategic interest. Senior decision-makers face an imperative to refine operational and portfolio strategies, aligning with clinical developments and shifting global dynamics to sustain both market growth and patient access.

Market Snapshot: Auranofin Market Size and Outlook

Global demand for auranofin is projected to expand from USD 230.02 million in 2025 to USD 247.73 million in 2026. The market will sustain a CAGR of 4.96%, with expectations to reach USD 322.96 million by 2032. This growth trajectory reflects the impact of research advances, changing care standards, and targeted commercialization efforts across multiple therapeutic areas. Senior executives should monitor the evolving policy and access landscape to optimize resource allocation and capitalize on regional shifts.

Auranofin Market: Scope & Segmentation

  • Indications: Oncology applications are advancing, especially for leukemia and lymphoma, augmented by a continued presence in rheumatoid arthritis. Both legacy and novel therapeutic opportunities are under development.
  • Therapeutic Classes: Gold compounds remain central, within the broader field of disease-modifying antirheumatic drugs (DMARDs). Biologics, targeted therapies, and conventional synthetic agents are shaping market dynamics and supporting expanded uses.
  • Distribution Channels: Hospital, online, and retail community pharmacies, together with specialty logistics providers, support complex access requirements, ensuring efficient patient reach and operational continuity.
  • End Users: Hospitals, specialty clinics, and home care environments each demand customized packaging options, remote monitoring, and practical solutions for medication adherence and safety.
  • Dosage Strengths: Available dose strengths, including 3mg and 6mg, support a range of commercial and clinical use cases, offering flexibility for titration strategies and streamlined manufacturing.
  • Regional Coverage: Americas, Europe, Middle East & Africa, and Asia-Pacific encompass varied regulatory frameworks, payer structures, and supply chains, informing market entry and risk diversification.
  • Technology Drivers: Translational biomarkers enhance personalized therapy, while adaptive clinical trial methods accelerate evidence generation. Digital pharmacy solutions and enhanced supply chain architectures are foundational for operational resilience and commercialization agility.

Key Takeaways for Senior Decision-Makers

  • Expanding clinical repurposing strategies are driven by robust mechanistic rationale, enabling new use cases for auranofin in oncology and immune-related therapeutic sectors.
  • Alignment across development, regulatory, commercial, and manufacturing teams is increasingly essential to support timely market entry and maintain evidence-based patient access.
  • Operational resilience remains a cornerstone, especially as supply chain safeguards are tested by geopolitical factors, demand variability, and region-specific requirements.
  • Market access now hinges on clear, customized value narratives for each distribution and payer channel, prioritizing early engagement and outcome-driven coverage.
  • Collaborative partnerships with research organizations, contract manufacturing firms, and digital distributors provide flexibility and risk mitigation, enabling accelerated launches and improved service continuity.

Tariff Impact: Navigating US Policy and Global Supply

Ongoing tariff policy adjustments in the United States are prompting auranofin suppliers to review and rebalance their global sourcing strategies. Diversification of supply sources and investments in nearshoring and inventory reserves are increasingly common, helping organizations manage compliance risks and buffer cost fluctuations. These adaptations ensure stability in manufacturing schedules and distribution operations, protecting clinical programs from disruption amid shifting trade protocols.

Methodology & Data Sources

This report synthesizes insights from structured interviews with leaders in clinical, regulatory, manufacturing, and commercial roles related to specialty therapies and drug repurposing. Secondary research spans peer-reviewed literature, clinical registries, patent records, and regulatory filings. Scenario analysis and peer validation underpin the robustness and applicability of all findings.

Why This Report Matters

  • Guides development and commercialization planning by clarifying opportunities and risks within oncology and rheumatology for auranofin.
  • Delivers targeted insights on how to mitigate supply chain and regulatory exposure, supporting operational continuity and compliance in turbulent policy environments.
  • Enables data-driven investment and partnership decisions by highlighting factors that influence clinical efficacy, market access, and operational strength.

Conclusion

Auranofin’s repositioning in therapy pipelines underscores the need for integrated strategies linking science, operations, and market execution. Stakeholders who emphasize coordinated action and regulatory foresight will drive sustained value and broaden patient access into emerging application areas.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Auranofin Market, by Indication
8.1. Oncology
8.1.1. Leukemia
8.1.2. Lymphoma
8.2. Rheumatoid Arthritis
8.2.1. Moderate
8.2.2. Severe
9. Auranofin Market, by Therapeutic Class
9.1. DMARDS
9.1.1. Biologics
9.1.2. Conventional
9.1.3. Targeted Synthetic
9.2. Gold Compounds
10. Auranofin Market, by Dosage Strength
10.1. 3mg
10.2. 6mg
11. Auranofin Market, by End User
11.1. Home Care Settings
11.2. Hospitals
11.3. Specialty Clinics
12. Auranofin Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies
13. Auranofin Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Auranofin Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Auranofin Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Auranofin Market
17. China Auranofin Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AGC Inc.
18.6. Ardagh Group S.A.
18.7. Corning Incorporated
18.8. Guardian Industries
18.9. Nippon Electric Glass Co. Ltd.
18.10. Owens-Illinois Inc.
18.11. Pilkington Group Limited
18.12. PPG Industries Inc.
18.13. Saint-Gobain S.A.
18.14. Schott AG
18.15. Vitro S.A.B. de C.V.
List of Figures
FIGURE 1. GLOBAL AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL AURANOFIN MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS AURANOFIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. EUROPE AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. EUROPE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 106. EUROPE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 107. EUROPE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 108. EUROPE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 109. EUROPE AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 110. EUROPE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 111. EUROPE AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. EUROPE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 124. AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 125. AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 126. AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 127. AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 128. AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 129. AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. ASEAN AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. ASEAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 143. ASEAN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 144. ASEAN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 145. ASEAN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 146. ASEAN AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 147. ASEAN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 148. ASEAN AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. ASEAN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150. GCC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GCC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 152. GCC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 153. GCC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 154. GCC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 155. GCC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 156. GCC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 157. GCC AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. GCC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. BRICS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. BRICS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 170. BRICS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 171. BRICS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 172. BRICS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 173. BRICS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 174. BRICS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 175. BRICS AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. BRICS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. G7 AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. G7 AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 179. G7 AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 180. G7 AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 181. G7 AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 182. G7 AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 183. G7 AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 184. G7 AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. G7 AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. NATO AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. NATO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 188. NATO AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 189. NATO AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 190. NATO AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 191. NATO AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 192. NATO AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 193. NATO AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. NATO AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 198. UNITED STATES AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 201. UNITED STATES AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. CHINA AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 206. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 207. CHINA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 208. CHINA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 209. CHINA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 210. CHINA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
TABLE 211. CHINA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 212. CHINA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. CHINA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Auranofin market report include:
  • AGC Inc.
  • Ardagh Group S.A.
  • Corning Incorporated
  • Guardian Industries
  • Nippon Electric Glass Co. Ltd.
  • Owens-Illinois Inc.
  • Pilkington Group Limited
  • PPG Industries Inc.
  • Saint-Gobain S.A.
  • Schott AG
  • Vitro S.A.B. de C.V.

Table Information

Report AttributeDetails
No. of Pages190
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 247.73 Million
Forecasted Market Value ( USD ) by 2032 $ 322.96 Million
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Auranofin (CAS 34031-32-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Auranofin (CAS 34031-32-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Filgotinib Tablets Market - Global Forecast 2026-2032 - Product Image

Filgotinib Tablets Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Dexamethasone Sodium Phosphate Active Pharmaceutical Ingredients Market - Global Forecast 2025-2030 - Product Image

Dexamethasone Sodium Phosphate Active Pharmaceutical Ingredients Market - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Methotrexate Drugs - Global Strategic Business Report - Product Image

Methotrexate Drugs - Global Strategic Business Report

  • Report
  • 564 Pages
  • Global
From
Rituximab - Global Strategic Business Report - Product Image

Rituximab - Global Strategic Business Report

  • Report
  • 378 Pages
  • Global
From

About the Market

Auranofin is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is an oral gold-based medication that works by suppressing the immune system and reducing inflammation. Auranofin is a relatively new drug, having been approved by the FDA in 1985. It is generally well-tolerated, with few side effects. Auranofin is used in combination with other medications to treat immune disorders. It is often prescribed in combination with non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). Auranofin is also used to treat other conditions, such as lupus and Sjogren's syndrome. The Auranofin market is a growing one, with many companies offering the drug. Some of the companies in the market include Mylan, Teva Pharmaceuticals, and Sandoz. Other companies, such as Pfizer, Merck, and Novartis, also offer Auranofin in some countries. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.